Medical Marijuana Inc. Product, CanChew Bio-Technologies
Founder Interviews With Small Cap Voice Internet Radio Program
SAN DIEGO, Aug. 23, 2012 /PRNewswire/ -- Medical Marijuana Inc. (OTC: MJNA), a leading hemp industry innovator, is pleased to welcome Dr. Philip Van Damme, Director for CanChew Biotechnologies, to Small Cap Voice's Internet radio network. Dr. Van Damme, a Netherlands-trained surgeon, is eager to share why and how he invented the revolutionary Non-THC CanChew gum. Its tremendous medical potential will offer a new treatment for pain-afflicted people in the U.S. and beyond.
The interview below, which is conducted by Small Cap Voice Internet radio host Stuart T. Smith, provides valuable insight into the history of CanChew Biotechnologies, which will announce a soft release product launch on September 15th in the U.S. with international markets to follow.
In the program, Dr. Van Damme points out that an important part of CanChew lies in its non-stigmatizing, legal medical delivery system. Unlike the harmful means of smoking medicinal marijuana, this specialized gum transports Non-THC cannabinoids through the body with the simple ease of the societally accepted act of chewing gum.
Its potential value to patients? Immense, Dr. Van Damme says. Chronic pain suffers, beginning and end stage cancer patients, even a person with anorexia, can see relief with CanChew. Dr. Van Damme adds that he put his heart into developing this product because patients in deep pain continuously confront him. He believes CanChew is a new vehicle-unlike any other on the market-that can offer them relief. As revenues of the product grow, he plans on using a portion to reinvest in scientific studies that continue to establish its medicinal potency.
CanChew® is a unique, socially acceptable, patient friendly, taste masked and convenient delivery format for delivery of cannabis/cannabinoid(s) based pharmaceuticals. The delivery of these medications via the oral mucosa provides for rapid and near complete absorption directly into the systemic circulation. This leads to rapid onset of effects and increased bioavailability. Pre-systemic metabolism is thus avoided. This system of delivery offers clearly improved economic opportunities compared to alternative drug delivery routes.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value.
Medical Marijuana Inc. does not grow, sell or distribute any substances that violate United States Law or the controlled substance act.
For more information, please visit the company's website at: www.MedicalMarijuanaInc.com
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration (FDA). These products and statements are not intended to diagnose, treat, cure, or prevent any disease.
Investor Relations Contact:
Stuart T. Smith
SOURCE Medical Marijuana Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.